Bardoxolone methyl

CAS No.	218600-53-4	Cat. No.	BCP04660
Name	Bardoxolone methyl
Synonyms	CDDO Methyl ester; CDDOMe; NSC 713200; RTA 402; RTA-402; RTA402; TP-155; TP155; TP 155;
Formula	C32H43NO4	M. Wt	505.69

Description	Bardoxolone methyl (also known as “RTA 402” and “CDDO-methyl ester”) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation. Bardoxolone methyl is currently being developed by Reata Pharmaceuticals, Inc. in partnership with Abbott Laboratories and Kyowa Hakko Kirin, for the treatment of advanced chronic kidney disease (CKD) in type 2 diabetes mellitus patients.
Pathways	NFκB
Targets	Keap1 Nrf2

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.